Pharsight

1. Clobex patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6106848	GALDERMA LABS LP	Topically applicable O/W emulsions having high glycol content and at least one biologically active agent	Sep, 2017 (6 years ago)
US5972920	GALDERMA LABS LP	Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders	Feb, 2018 (6 years ago)
US5990100	GALDERMA LABS LP	Composition and method for treatment of psoriasis	Mar, 2018 (6 years ago)

Market Authorisation Date: 24 July, 2003

Treatment: Twice daily topical treatment of moderate to severe plaque psoriasis.

Dosage: SPRAY;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0005	27 Mar, 2006	1	04 Dec, 2008	22 Sep, 2017	Eligible
0.0005	29 Sep, 2008	1	16 Jun, 2011	24 Mar, 2018	Eligible
0.0005	09 Jan, 2008	1	07 Jun, 2011	17 Jun, 2019	Non-Forfeiture

Strength	Dosage	Availability
0.05%	SPRAY;TOPICAL	Prescription

CLOBEX family patents

2. Clobex patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8066975	GALDERMA LABS	Foaming composition for washing and treating hair and/or scalp based on an active principle	Jun, 2019 (4 years ago)
US7316810	GALDERMA LABS	Foaming composition for washing and treating hair and/or scalp based on an active principle	Jun, 2019 (4 years ago)
US8066976	GALDERMA LABS	Foaming compositions for hair care	Jun, 2019 (4 years ago)
US7700081	GALDERMA LABS	Foaming compositions for hair care	Jan, 2022 (2 years ago)

Market Authorisation Date: 05 February, 2004

Treatment: Topical treatment of scalp psoriasis

Dosage: SHAMPOO;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0005	27 Mar, 2006	1	04 Dec, 2008	22 Sep, 2017	Eligible
0.0005	29 Sep, 2008	1	16 Jun, 2011	24 Mar, 2018	Eligible
0.0005	09 Jan, 2008	1	07 Jun, 2011	17 Jun, 2019	Non-Forfeiture

Strength	Dosage	Availability
0.05%	SHAMPOO;TOPICAL	Prescription

CLOBEX family patents

3. Impoyz patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10588914	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (6 years from now)
US10064875	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (6 years from now)
US9956231	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (6 years from now)
US9855334	PRIMUS PHARMS	Topical compositions comprising a corticosteroid	Mar, 2035 (10 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Nov 28, 2020

Market Authorisation Date: 28 November, 2017

Treatment: Treatment of moderate to severe plaque psoriasis in patients 18 years of age or older; Twice daily topical treatment of moderate to severe plaque psoriasis.; Plaque psoriasis

Dosage: CREAM;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.00025	06 Dec, 2019	1		11 Mar, 2035

Strength	Dosage	Availability
0.025%	CREAM;TOPICAL	Prescription

IMPOYZ family patents

4. Olux patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6126920	MYLAN	Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition	Mar, 2016 (8 years ago)

Market Authorisation Date: 26 May, 2000

Treatment: Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition

Dosage: AEROSOL, FOAM;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0005	27 Jun, 2005	1	10 Mar, 2008	03 Oct, 2017	Eligible

Strength	Dosage	Availability
0.05%	AEROSOL, FOAM;TOPICAL	Discontinued

OLUX family patents

5. Olux E patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP05775966A	2014-05-14	Henkel AG & Co. KGaA	Patent maintained as amended
EP05775966A	2014-05-14	Generics [UK] Limited	Patent maintained as amended

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6730288	MYLAN	Mousse composition	Sep, 2019 (4 years ago)
US7029659	MYLAN	Mousse composition	Sep, 2019 (4 years ago)
US8962000	MYLAN	Microemulsion and sub-micron emulsion process and compositions	Aug, 2025 (1 year, 4 months from now)
US8460641	MYLAN	Microemulsion process and composition	Nov, 2028 (4 years from now)

Market Authorisation Date: 12 January, 2007

Treatment: Treatment of corticosteroid-responsive dermatoses

Dosage: AEROSOL, FOAM;TOPICAL

Pharsight

Drugs that contain Clobetasol Propionate

1. Clobex patents expiration

CLOBEX family patents

2. Clobex patents expiration

CLOBEX family patents

3. Impoyz patents expiration

IMPOYZ family patents

4. Olux patents expiration

OLUX family patents

5. Olux E patents expiration

OLUX E family patents

Related content